Knight Therapeutics stock analysis
Want to see TSE:GUD full AI Analyst Report?
Knight Therapeutics (GUD) Stock Price & Analysis
GUD Stock Chart & Stats
- Day’s Range
- CAD 11.89 - CAD 12.12
- 52-Week Range
- CAD 5.66 - CAD 12.17
- Previous Close
- CAD 11.98
- Volume
- N/A
- Average Volume (3M)
- 68.94K
- Market Cap
- CAD 1.18B
- Enterprise Value
- CAD 936.94M
- Total Cash (Recent Filing)
- CAD 147.83M
- Total Debt (Recent Filing)
- CAD 33.52M
- Price to Earnings (P/E)
- 77.6
- Beta
- 0.38
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- 0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue And EBITDA Growth
Rapid revenue and EBITDA growth indicates that Knight is converting product launches and promoted medicines into meaningful commercial scale. Raised annual guidance reinforces the durability of current execution, while stronger earnings provide additional resources to support future launches and business development.
Strong Cash Generation And Low Leverage
Robust operating and free cash flow, combined with very low leverage, gives Knight financial flexibility to fund regulatory work, commercial expansion, acquisitions, and licensing transactions. This reduces solvency pressure and supports continued investment without relying heavily on additional borrowing.
Broad Launch Pipeline And Commercial Infrastructure
A broad pipeline diversified across Canada and Latin America can support multi-year growth beyond the current product base. The majority of potential revenue comes from already approved products, which may reduce development uncertainty and allow Knight's regulatory, medical, and commercial infrastructure to compound launch productivity.
Bears Say
AmBisome Generic Competition
Generic entry creates a defined medium-term threat to an existing revenue and EBITDA contributor in Brazil. The expected pressure could weaken portfolio profitability and require growth from newer products to offset the loss, making execution across the pipeline important to sustaining earnings power.
Thin And Volatile Profitability
The recent earnings recovery has not yet produced a consistently strong margin profile. Thin net profitability leaves less protection against product mix, pricing, or expense changes, while prior losses and lower gross margin show that reported earnings can remain sensitive as the portfolio evolves.
Higher Operating Expense Burden
Higher spending on launches, sales infrastructure, administration, and legal matters is limiting the conversion of revenue growth into adjusted EBITDA. Although some investment supports future products, sustained expense growth raises the execution threshold and could delay margin expansion if launches do not scale as planned.
Knight Therapeutics News
GUD FAQ
What was Knight Therapeutics’s price range in the past 12 months?
What is Knight Therapeutics’s market cap?
When is Knight Therapeutics’s upcoming earnings report date?
How were Knight Therapeutics’s earnings last quarter?
Is Knight Therapeutics overvalued?
Does Knight Therapeutics pay dividends?
What is Knight Therapeutics’s EPS estimate?
How many shares outstanding does Knight Therapeutics have?
What happened to Knight Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Knight Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Knight Therapeutics Stock Smart Score
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a diverse portfolio encompassing pharmaceutical products, consumer health goods, and medical devices. Its extensive product catalog features treatments such as Nerlynx, prescribed for extended adjuvant and metastatic breast cancer; Tafasitamab, used for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib, targeting metastatic cholangiocarcinoma; Trelstar, addressing advanced prostate cancer and pain associated with endometriosis; Vidaza, indicated for myelodysplastic syndrome; Abraxane, for metastatic pancreatic adenocarcinoma; Halaven, for metastatic breast cancer and soft tissue sarcoma; and Lenvima, useful in differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company's offerings further include Ladevina, for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix, for metastatic prostate cancer; Karfib, for relapsed or refractory multiple myeloma; Leprid, for advanced prostate cancer; and Rembre, for chronic myeloid leukemia. For infectious diseases, it provides Ambisome and Cresemba for fungal infections, along with Impavido for leishmaniasis. Other notable products include Exelon, managing mild to moderately severe dementia; Ibsrela, for irritable bowel syndrome with constipation; Salofalk, for ulcerative colitis; Ursofalk, to treat biliary cirrhosis; Imvexxy, for moderate to severe dyspareunia; Bijuva, for moderate to severe vasomotor symptoms linked to menopause in women with intact uteri; Fibridoner, for idiopathic pulmonary fibrosis; Toliscrin DPI, addressing pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2, for severe acute or resistant chronic infections; and Tobradosa Haler, for chronic lung infections. Beyond its product-focused endeavors, Knight Therapeutics Inc. also provides financing to other life science companies and makes strategic investments in life sciences venture capital funds.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Samira Sakhia
- Employees
- 830
- Website
- www.knighttx.com
- Address
- 100 Boul. Alexis-Nihon, Montreal, QC, H4M 2P2, CA
Knight Therapeutics (GUD) Earnings & Revenues
GUD Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by record nine-month results, double-digit quarterly growth, raised revenue and adjusted EBITDA guidance, expanded peak revenue potential, strong cash generation, successful product launches, and continued business development momentum. The main challenges were expected pressure on AmBisome from generic competition beginning in 2027, a decline in the promoted strategic portfolio, higher operating expenses, and pending regulatory work for certain products. Management nevertheless characterized current product performance, margins, and the longer-term outlook favorably.
View all TSE:GUD earnings summariesGUD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 4 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 12 | 0 | 0 |
